FrancophonIA/ELRC3.0 huggingface dataset:
English: Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Maltese: 41 mg dextromethorphan u quinidine sulfate dihydrate, ekwivalenti għal 8.69 mg quinidine.
English: • thioridazine, a medicine used in the treatment of schizophrenia and psychosis, that may affect the heart,
Maltese: • thioridazine, mediċina użata fil-kura tal-iskiżofrenija u l-psikosi, li tista' taffettwa l-qalb,
English: In a drug-drug interaction study, a higher combination dose of dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) was added to paroxetine at steady state.
Maltese: Fi studju ta' interazzjoni bejn il-mediċini, doża kombinata aktar għolja ta' dextromethorphan/quinidine (dextromethorphan 23 mg/quinidine 26 mg) ġiet miżjuda ma' paroxetine fl-istat fiss.
English: Drug interactions with desipramine and paroxetine have been studied in controlled clinical trials with a higher dose combination of dextromethorphan/quinidine (dextromethorphan 23 mg/ quinidine 26 mg) than in this medicinal product; study results are described below.
Maltese: L-interazzjonijiet tal-mediċini b'desipramine u paroxetine ġew studjati fi provi kliniċi kkontrollati b'kombinazzjoni ta' dożi aktar għoljin ta' dextromethorphan/quinidine (dextromethorphan 23 mg/ quinidine 26 mg) milli f'dan il-prodott mediċinali; ir-riżultati tal-istudju huma deskritti hawn isfel.
English: Each NUEDEXTA 15 mg/9 mg capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine.
Maltese: Kull NUEDEXTA kapsula ta' 15 mg/9 mg fiha dextromethorphan hydrobromide monohydrate, ekwivalenti għal 15.
English: Evaluation and treatment of overdose is based on experience with the individual components, dextromethorphan and quinidine.
Maltese: L-evalwazzjoni u l-kura ta' doża eċċessiva huma bbażati fuq l-esperjenza bil-komponenti individwali, dextromethorphan u quinidine.
English: • teeth grinding (bruxism), confusion, depressed mood, depression, disorientation (e.g. difficulty sensing time, direction, and recognition of people and places), early morning awakening,
Maltese: • tgħażżiż tas-snien (tgħażżiż tas-snien involontarju jew abitwali), konfużjoni, burdata depressa, depressjoni, diżorjentament (eż. diffikultà biex tagħraf il-ħin, id-direzzjoni u l-għarfien ta' persuni u postijiet), qawmien filgħodu kmieni, tnaqqis fl-espressività emozzjonali (nuqqas ta' rispons emottiv), alluċinazzjoni, imġiba impulsiva, indifferenza, nuqqas ta' rqad, irrekwitezza, disturb fl-irqad
English: In such UM patients, dextromethorphan is rapidly metabolised, leading to lower, potentially subtherapeutic concentrations.
Maltese: F'pazjenti UM bħal dawn, dextromethorphan jiġi metabolizzat rapidament, li jwassal għal konċentrazzjonijiet aktar baxxi, possibbilment subterapewtiċi.
English: Dextromethorphan is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist.
Maltese: Dextromethorphan ma inibixxa (<20% inibizzjoni) l-ebda wieħed mill-isoenzimi ttestjati:
English: The selective serotonin reuptake inhibitor (SSRI) paroxetine is metabolized primarily by CYP2D6 and is also a potent CYP2D6 inhibitor.
Maltese: L-inibitur selettiv tat-teħid mill-ġdid tas-serotonin (SSRI), paroxetine, jiġi metabolizzat prinċipalment minn CYP2D6 u huwa inibitur qawwi ta' CYP2D6.
English: LVH and LVD are more likely to be present in patients with chronic hypertension, known coronary artery disease or history of stroke.
Maltese: Il-LVH u l-LVD huma aktar probabbli li jkunu preżenti f'pazjenti bi pressjoni għolja kronika, mard magħruf tal-arterji koronarji jew storja ta' puplesija.
English: High density polyethylene (HDPE) bottle with a child resistant polypropylene cap. Each bottle is packed in a carton.
Maltese: Flixkun tal-polyethylene b'densità għolja (high density polyethylene) (HDPE) b'tapp talpolypropylene li huwa reżistenti għat-tfal.
English: Based on the results of transporter inhibition studies drug-drug interactions related to dextromethorphan inhibition of P-gp, OATP1B1, OATP1B3, OCT2, OAT1, OAT3 or BSEP are not expected during treatment withNUEDEXTA.
Maltese: Fuq il-bażi tar-riżultati tal-istudji dwar l-inibizzjoni tat-trasportaturi, mhumiex mistennija interazzjonijiet bejn il-mediċini relatati mal-inibizzjoni ta' P-gp, OATP1B1, OATP1B3, OCT2, OAT1, OAT3 jew BSEP minn dextromethorphan waqt kura b'NEUDEXTA.
English: Concomitant use of CYP2D6 substrates/inhibitors
Maltese: Użu konkomitanti ta' substrati/inibituri ta' CYP2D6
English: If the clinical response with NUEDEXTA 15 mg/9 mg is inadequate, NUEDEXTA 23 mg/9 mg should be prescribed, taken two times per day, one in the morning and one in the evening, 12 hours apart.
Maltese: Jekk ir-rispons kliniku b'NUEDEXTA 15 mg/9 mg ma jkunx adegwat, għandu jingħata NUEDEXTA 23 mg/9 mg, meħud darbtejn kuljum, waħda filgħodu u waħda filgħaxija, 12-il siegħa 'l bogħod minn xulxin.
English: Gastric lavage may be of use.
Maltese: Jista' jkollok bżonn terġa' taqrah.
English: The educational material for HCPs should assist them in the collection and assessment of relevant patient's details on pre-existing co-morbidities and concomitant medications prior to initiating Nuedexta therapy.
Maltese: Il-materjal edukattiv għall-HCPs għandu jgħinhom fil-ġbir u fil-valutazzjoni tad-dettalji tal-pazjent relevanti fuq komorbiditajiet pre-eżistenti u medikazzjonijiet konkomitanti qabel il-bidu tal-kura b'Nuedexta.
English: • atomoxetine, used to treat attention-deficit hyperactivity disorder (ADHD)
Maltese: • atomoxetine, użat għall-kura tad-disturb ta' nuqqas ta' attenzjoni u ta' attività eċċessiva
English: EMA/895559/2018 EMEA/H/C/001129
Maltese: EMA/895559/2018 EMA/H/C/001129
English: Leflunomide Zentiva1 (leflunomide)
Maltese: Leflunomide Zentiva1 (leflunomid)
English: Leflunomide Zentiva is available as tablets (10 mg, 20 mg and 100 mg).
Maltese: Leflunomide Zentiva jiġi bħala pilloli (10 mg, 20 mg u 100 mg).
English: • severe immunodeficiency states, such as acquired immune deficiency syndrome (AIDS);
Maltese: • stati ta' immunodefiċjenza severa, bħas-sindrome tal-immunodefiċjenza akkwiżita (AIDS);
English: Further information on Leflunomide Zentiva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/leflunomide-zentiva.
Maltese: Aktar informazzjoni dwar Leflunomide Zentiva tinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/leflunomide-zentiva.
English: The most common side effects with Leflunomide Zentiva (which may affect up to 1 in 10 people) are leucopenia (low white blood cell counts), mild allergic reactions, increased creatine phosphokinase levels (a marker of muscle damage), paraesthesia (abnormal sensations like pins and needles), peripheral neuropathy (nerve damage in hands and feet), headache, dizziness, mild increases in blood pressure, colitis (inflammation in the large bowel), diarrhoea, nausea (feeling sick), vomiting, inflammation of the mouth such as mouth ulcers, abdominal (belly) pain, increased liver enzyme levels, hair loss, eczema, rash, pruritus (itching), dry skin, tenosynovitis (inflammation of the sheath surrounding the tendons), loss of appetite, weight loss and asthenia (weakness).
Maltese: L-effetti sekondarji l-aktar komuni b'Leflunomide Zentiva (li jistgħu jaffettwaw sa persuna 1 minn kull 10) huma l-lewkopenija (għadd baxx taċ-ċelloli bojod tad-demm), reazzjonijiet allerġiċi ħfief, żieda filkreatina fil-livelli fosfokinażi (markatur tal-ħsara muskolari), parestesija (sensazzjonijiet anormali bħal tingiż) newropatija periferali (ħsara fin-nervituri fl-idejn u fis-saqajn), uġigħ ta' ras, sturdament, żidiet ħfief fil-pressjoni tad-demm, kolite (infjammazzjoni fil-musrana l-kbira), dijarrea, nawżja (tħossok ma tiflaħx), rimettar, infjammazzjoni tal-ħalq bħal ulċeri fil-ħalq, uġigħ addominali (żaqq), żieda fil-livelli tal-enzimi tal-fwied, telf tax-xagħar, ekżema, raxx, prurite (ħakk), ġilda xotta, tenosinovite (infjammazzjoni tal-għant madwar l-għeruq), telf ta' aptit, telf fil-piż u astenija (dgħufija).
English: • serious infections;
Maltese: • infezzjonijiet serji;
English: The medicine usually starts to have an effect after 4 to 6 weeks.
Maltese: Il-mediċina normalment jibda jkollha effett wara 4 sa 6 ġimgħat.
English: Leflunomide Zentiva received a marketing authorisation valid throughout the EU on 8 January 2010.
Maltese: Leflunomide Zentiva ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-8 ta' Jannar 2010.
English: 1 Previously known as Leflunomide Winthrop.
Maltese: 1Qabel magħruf bħala Leflunomide Winthrop.
English: Other information about Leflunomide Zentiva
Maltese: Informazzjoni oħra dwar Leflunomide Zentiva
English: The active substance in Leflunomide Zentiva, leflunomide, is an immunosuppressant.
Maltese: Is-sustanza attiva f'Leflunomide Zentiva, il-leflunomid, hija immunosoppressiv.
English: The medicine contains the active substance leflunomide.
Maltese: Il-mediċina fiha s-sustanza attiva leflunomid.
English: • severe hypoproteinaemia (low blood protein levels).
Maltese: • ipoproteinemija severa (livelli baxxi ta' proteini fid-demm).
English: In psoriatic arthritis, a study in 186 patients showed that Leflunomide Zentiva was more effective than placebo over 6 months: 59% of the patients taking Leflunomide Zentiva responded to treatment, compared with 30% of those taking placebo.
Maltese: Fl-artrite psorjatika, studju f'186 pazjent wera li Leflunomide Zentiva kien aktar effettiv minn plaċebo tul 6 xhur: 59 % tal-pazjenti li kienu qed jieħdu Leflunomide Zentiva rrispondew għall-kura, meta mqabbla ma' 30 % ta' dawk li kienu qed jieħdu plaċebo.
English: Between 49 and 55% of the patients taking Leflunomide Zentiva responded to treatment, compared with 26 to 28% of those taking placebo, and 54% of those taking sulphasalazine.
Maltese: Bejn 49 u 55 % tal-pazjenti li kienu qed jieħdu Leflunomide Zentiva rrispondew għall-kura, meta mqabbla ma' 26 sa 28% ta' dawk li kienu qed jieħdu plaċebo, u 54 % ta' dawk li kienu qed jieħdu sulfalazine.
English: The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis.
Maltese: Id-doża ta' manteniment rakkomandata hija ta' 10 sa 20 mg darba kuljum f'pazjenti bl-artrite rewmatojde, u 20 mg darba kuljum f'pazjenti bl-artrite psorjatika.
English: • moderate to severely impaired kidney function;
Maltese: • funzjoni tal-kliewi indebolita minn moderata sa severa;
English: In rheumatoid arthritis, Leflunomide Zentiva has been studied in 4 main studies involving over 2,000 patients, in which it was compared with placebo (a dummy treatment), or with methotrexate or sulphasalazine (other medicines used to treat rheumatoid arthritis).
Maltese: Fl-artrite rewmatojde, Leflunomide Zentiva ġie studjat f'4 studji ewlenin li involvew aktar minn 2,000 pazjent, li fihom tqabbel ma' plaċebo (kura finta), jew ma' methotrexate jew sulphalazine (mediċini oħrajn użati għall-kura tal-artrite rewmatojde).
English: How does Leflunomide Zentiva work?
Maltese: Leflunomide Zentiva?
English: Leflunomide Zentiva is a medicine used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints).
Maltese: Leflunomide Zentiva huwa mediċina li tintuża biex tikkura adulti b'artrite rewmatojde attiva (marda tas-sistema immunitarja li tikkawża infjammazzjoni tal-ġogi) jew artrite psorjatika attiva (marda li tikkawża rqajja' ħomor, bil-qxur fuq il-ġilda u infjammazzjoni tal-ġogi).
English: Results showed that Leflunomide Zentiva was more effective than placebo and as effective as sulphasalazine.
Maltese: Ir-riżultati wrew li Leflunomide Zentiva kien aktar effettiv minn plaċebo u effettiv daqs sulphalazine.
English: What are the risks associated with Leflunomide Zentiva?
Maltese: X'inhuma r-riskji assoċjati ma' Leflunomide Zentiva?
English: Leflunomide Zentiva treatment usually starts with a ‘loading dose' of 100 mg once a day for 3 days, followed by a maintenance dose.
Maltese: Il-kura b'Leflunomide Zentiva normalment tibda b'“doża ta' tagħbija” ta' 100 mg darba kuljum għal 3 ijiem, segwita minn doża ta' manteniment.
English: As for all medicines, data on the use of Leflunomide Zentiva are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Leflunomide Zentiva hija ssorveljata kontinwament.
English: The company that markets Leflunomide Zentiva will ensure that doctors who are expected to prescribe the medicine receive an information pack containing important information on the risks with Leflunomide Zentiva and the monitoring that should be carried out in patients.
Maltese: Il-kumpanija li tqiegħed Leflunomide Zentiva fis-suq ser tiżgura li t-tobba li huma mistennija jippreskrivu l-mediċina jirċievu pakkett ta' informazzjoni dwar ir-riskji b'Leflunomide Zentiva u lmonitoraġġ li għandu jsir fuq il-pazjenti.
English: Leflunomide Zentiva was not as effective as methotrexate in the extension study.
Maltese: Leflunomide Zentiva ma kienx effettiv daqs methotrexate fl-istudju ta' estensjoni.
English: Doctors prescribing Leflunomide Zentiva need to be aware of the risk of liver problems associated with the medicine.
Maltese: It-tobba li jippreskrivu Leflunomide Zentiva jeħtieġ li jkunu konxji mir-riskju ta' problemi fil-fwied assoċjati mal-mediċina.
English: Over the first year of treatment, Leflunomide Zentiva was as effective as methotrexate, but only when it was taken with folate (a type of vitamin B).
Maltese: Matul l-ewwel sena tal-kura, Leflunomide Zentiva kien effettiv daqs methotrexate, iżda meta ttieħed mal-folat biss (tip ta' vitamina B).
English: With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis.
Maltese: B'inqas limfoċti, ikun hemm inqas infjammazzjoni, li jgħin jikkontrolla s-sintomi tal-artrite.
English: Why is Leflunomide Zentiva authorised in the EU?
Maltese: Għalfejn Leflunomide Zentiva ġie awtorizzat fl-UE?
English: Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply.
Maltese: Il-leflunomid tagħmel dan billi timblokka enzima msejħa "dejidrorotat deidroġenażi", li hija meħtieġa biex il-limfoċiti jimmultiplikaw.
English: An overview of Leflunomide Zentiva and why it is authorised in the EU
Maltese: Ħarsa ġenerali lejn Leflunomide Zentiva u għalfejn huwa awtorizzat fl-UE
English: It is available as tablets (0.5 and 1 mg).
Maltese: Jiġi bħala pilloli (0.5 u 1 mg).
English: The full EPAR for Champix can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ ta' Champix jinstab fis-sit elettroniku tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The percentage in the patients who had taken bupropion was 16%.
Maltese: Il-perċentwal fil-pazjenti li kienu ħadu bupropion kien 16%.
English: Champix is a medicine that contains the active substance varenicline.
Maltese: Champix huwa mediċina li fiha s-sustanza attiva vareniċlina.
English: This is a summary of the European public assessment report (EPAR) for Champix.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Champix.
English: The percentage of patients who had not smoked at all during weeks 9-12 was 44% with Champix, 30% with bupropion, and 18% with placebo.
Maltese: Il-perċentwal ta' pazjenti li ma kienu pejpu xejn matul il-ġimgħa 9 u l-ġimgħa 12 kien 44% b'Champix, 30% bi bupropion, u 18% bi plaċebo.
English: People who smoke become addicted to nicotine, a chemical in tobacco.
Maltese: Il-persuni li jpejpu jsiru vvizzjati bin-nikotina, kimika fit-tabakk.
English: In two main studies 2,052 smokers received 12-week treatment with Champix, bupropion (another non-nicotine medicine) or placebo (a dummy treatment).
Maltese: F'żewġ studji prinċipali 2,052 persuna li tpejjep irċevew 12-il ġimgħa ta' kura b'Champix, bi bupropion (mediċina oħra kontra n-nikotina) jew plaċebo (trattament finta).
English: The most common side-effects with Champix (seen in more than 1 patient in 10) are nausea (feeling sick), insomnia (difficulty sleeping), abnormal dreams, headache and nasopharyngitis (inflammation of the nose and throat).
Maltese: L-effetti sekondarji l-aktar komuni b'Champix (li dehru f'aktar minn pazjent 1 minn 10) huma nawżja (dardir), insomnja (diffikultà biex torqod), ħolm anormali, uġigħ ta' ras u nasofarinġite (infjammazzjoni tal-imnieħer u tal-griżmejn).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Champix on 26 September 2006.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Champix valida fl-Unjoni Ewropea kollha fis-26 ta' Settembru 2006.
English: The active substance in Champix, varenicline, can bind to some of these receptors, the α4β2 nicotinic acetylcholine receptors.
Maltese: Is-sustanza attiva f'Champix, il-vareniċlina, tista' teħel ma' xi wħud minn dawn ir-riċetturi, ir-riċetturi aċetikolini nikotiniċi α4β2.
English: More patients remained non-smokers after treatment with Champix than after placebo: 40 weeks after the end of the treatment period, the percentage of patients who were still non-smokers was 23% among those who had taken Champix, and 9% among those who had taken a placebo.
Maltese: Aktar pazjenti baqgħu ma jpejpux wara l-kura b'Champix milli wara plaċebo: 40 ġimgħa wara t-tmiem tal-perjodu tal-kura, il-perċentwal ta' pazjenti li baqgħu ma jpejpux kien 23% fost dawk li kienu ħadu Champix, u 9% fost dawk li kienu ħadu plaċebo.
English: Why has Champix been approved?
Maltese: Għaliex ġie approvat Champix?
English: The main measure of effectiveness was the number of patients who had completely stopped smoking for four weeks (between week 9 and week 12 of the study), confirmed by laboratory testing of the patients' breath for signs of smoking.
Maltese: Il-kejl ewlieni tal-effikaċja kien in-numru ta' pazjenti li waqfu jpejpu kompletament għal erba' ġimgħat (bejn il-ġimgħa 9 u lġimgħa 12 tal-istudju), ikkonfermat b'testijiet tan-nifs tal-pazjenti li saru f'laboratorji għal sinjali ta' tipjip.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku vareniċlina
English: A risk management plan has been developed to ensure that Champix is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Champix jintuża bl-aktar mod sigur possibbli.
English: Nicotine acts in the nervous system, where it binds to receptors and triggers the release of a chemical messenger, dopamine, which plays a part in the pleasure derived from smoking.
Maltese: In-nikotina taħdem fis-sistema nervuża, fejn teħel ma' riċetturi u tistimula r-rilaxx ta' messaġġier kimiku, dopamina, li għandha parti fil-pjaċir li jittieħed mit-tipjip.
English: Champix varenicline
Maltese: Kif jintuża Champix?
English: In the first week the patient takes one 0.5 mg tablet once a day for three days, followed by one 0.5 mg tablet twice a day for four days.
Maltese: Fl-ewwel ġimgħa lpazjent jieħu pillola waħda ta' 0.5 mg darba kuljum għal tlitt ijiem, segwiti b'pillola waħda ta' 0.5 mg darbtejn kuljum għal erbat ijiem.
English: When binding to these receptors, varenicline acts in two ways: it acts like nicotine (partial agonist) and this helps to relieve craving symptoms, but it also acts against nicotine (antagonist), by taking its place, and this helps to reduce the pleasurable effects of smoking.
Maltese: Meta jeħel ma' dawn ir-riċetturi, il-vareniċlina jaġixxi b'żewġ modi: jaġixxi bħala nikotina (agonist parzjali) u dan jgħin biex itaffi s-sintomi tax-xenqa, iżda jaġixxi wkoll kontra nnikotina (antagonist), billi jieħu postha, u dan jgħin biex jitnaqqsu l-effetti ta' pjaċir mit-tipjip.
English: Another study compared Champix with placebo in patients who were allowed to choose their own target dates for quitting, which could be between one week and five weeks of starting treatment.
Maltese: Studju ieħor qabbel Champix ma' plaċebo f'pazjenti li kellhom permess jagħżlu d-dati fil-mira tagħhom stess biex jieqfu mit-tipjip, li setgħet tkun bejn ġimgħa u ħames ġimgħat mill-bidu tal-kura.
English: What is Champix?
Maltese: X'inhu Champix?
English: What is the risk associated with Champix?
Maltese: X'inhu r-riskju assoċjat ma' Champix?
English: Reduced doses may be used in patients who do not tolerate the medicine or who have kidney problems.
Maltese: F'pazjenti li mhumiex tolleranti għall-mediċina jew li jkollhom problemi fil-kliewi jistgħu jintużaw dożi mnaqqsin.
English: For the full list of all side effects and restrictions with Champix, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet kollha b'Champix, ara l-fuljett ta' tagħrif.
English: The CHMP concluded that the benefits of Champix outweigh its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Champix huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: How has Champix been studied?
Maltese: Kif ġie studjat Champix?
English: The patients' target date for quitting was set at one week after starting treatment and the patients were followed up for a further 40 weeks after their treatment to see if they started smoking again.
Maltese: Id-data fil-mira tal-pazjenti biex jieqfu mit-tipjip kienet stabbilita għal ġimgħa wara l-bidu tal-kura u l-pazjenti ġew segwiti għal 40 ġimgħa oħra wara l-kura li ħadu biex jiġi verifikat jekk reġgħux bdew ipejpu.
English: Other information about Champix
Maltese: Għal xiex jintuża Champix?
English: Patients set themselves a target date for quitting and will usually start taking Champix one to two weeks before this date.
Maltese: Il-pazjenti jistabbilixxu data partikolari biex jieqfu u normalment jibdew jieħdu Champix ġimgħa jew ħmistax qabel din id-data.
English: For the remaining 11 weeks of treatment, the patient takes one 1 mg tablet twice a day.
Maltese: Għall-bqija tal-11-il ġimgħa ta' kura, il-pazjent jieħu pillola waħda ta' 1 mg darbtejn kuljum.
English: EMA/717174/2015 EMEA/H/C/001236
Maltese: EMA/H/C/001236
English: The full EPAR for Lamivudine/Zidovudine Teva can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ ta' Lamivudine/Zidovudine Teva jinsab fis-sit web tal-Aġenzija ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Both active substances in Lamivudine/Zidovudine Teva, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs).
Maltese: Iż-żewġ sustanzi attivi f'Lamivudine/Zidovudine Teva, il-lamivudina u z-zidovudina, huma inibituri nukleosidiċi tat-transkrittażi inversa (nucleoside reverse transcriptase inhibitors) (NRTIs).
English: Lamivudine/Zidovudine Teva is a medicine that contains two active substances, lamivudine (150 mg) and zidovudine (300 mg).
Maltese: Lamivudine/Zidovudine Teva huwa mediċina li fiha żewġ sustanzi attivi, il-lamivudina (150 mg) u zzidovudina (300 mg).
English: Lamivudine/Zidovudine Teva is a ‘generic medicine'.
Maltese: Lamivudine/Zidovudine Teva huwa ‘mediċina ġenerika'.
English: This is a summary of the European public assessment report (EPAR) for Lamivudine/Zidovudine Teva.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Lamivudine/Zidovudine Teva.
English: The CHMP concluded that, in accordance with EU requirements, Lamivudine/Zidovudine Teva has been shown to have comparable quality and to be bioequivalent to Combivir.
Maltese: Is-CHMP ikkonkluda li, b'konformità mar-rekwiżiti tal-UE, intwera li l-kwalità ta' Lamivudine/Zidovudine Teva hija komparabbli ma' dik ta' Combivir u hija bijoekwivalenti għaliha.